Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2016-11-16 Report Publication Anno…
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Parution de la Lettre aux actionnaires de novembre 2016
Report Publication Announcement Classification · 99% confidence The document is a press release titled "Communiqué de presse" announcing the publication of the "Lettre aux actionnaires de novembre 2016" (Shareholder Letter of November 2016). It details the contents of the letter (editorial, news, portrait, shareholder guide) and provides a direct link to download the PDF. Since the document itself is an announcement about the release of another report (the Shareholder Letter) and is very short (2698 characters), it fits the definition of a Report Publication Announcement (RPA) according to Rule 2, which states that short documents announcing the publication of a report should be classified as RPA. While 'Lettre aux actionnaires' might suggest an Investor Presentation (IP) or similar, the primary function of this specific text is the announcement of availability.
2016-11-16 French
Quantum Genomics reports positive top-line results from Phase IIa trial of QGC001 in hypertension
Earnings Release Classification · 98% confidence The document is explicitly titled "Press release" and announces "positive top-line results from Phase IIa trial of QGC001 in hypertension." It details clinical trial progress, interactions with the FDA (Pre-IND meeting), and plans for future studies. This content is characteristic of an initial announcement of periodic financial or operational results, focusing on key achievements rather than providing the full, detailed financial statements found in an Annual Report (10-K) or Interim Report (IR). Therefore, it fits best under the Earnings Release (ER) category, which covers initial announcements of periodical results/key highlights. FY 2016
2016-09-29 English
Quantum Genomics annonce des résultats positifs pour l'étude clinique de phase IIa de QGC001 dans l'hypertension artérielle
Earnings Release Classification · 85% confidence The document is titled "Communiqué de presse" (Press Release) and announces positive results from a Phase IIa clinical study for a drug candidate (QGC001) in treating arterial hypertension. It details clinical trial design, quotes management, mentions upcoming communication at a medical congress, and discusses interactions with the FDA regarding future IND filings. This content is characteristic of an initial announcement of key scientific/clinical progress, which aligns best with an Earnings Release (ER) if it were financial results, but since it is a specific clinical trial update, it functions as a major corporate/scientific update. Given the options, this type of announcement, which is often released outside of standard quarterly earnings cycles to inform investors of significant operational milestones, is frequently categorized as an Earnings Release (ER) in broad financial databases, or sometimes as a Regulatory Filing (RNS) if it were a mandatory disclosure. However, since it is a press release detailing operational progress (clinical trial results), and not a formal financial report (10-K, IR) or a simple announcement of a report's publication (RPA), ER is the closest fit for a major operational update, although it is not strictly 'earnings'. Given the context of a major operational milestone announcement via press release, and lacking a specific 'Clinical Trial Update' code, ER is often used for significant, time-sensitive corporate news releases. Since it is a detailed announcement rather than a short notice, it is not RPA/RNS. FY 2016
2016-09-29 French
Quantum Genomics organise une conférence téléphonique le 29 septembre 2016 pour présenter les principaux résultats de l'étude clinique de phase IIa de QGC001 dans l'hypertension artérielle
Call Transcript Classification · 95% confidence The document is a press release announcing a conference call scheduled for September 29, 2016, to present key results from a Phase IIa clinical study (QGC001 for hypertension). The text explicitly details the date, time, dial-in numbers, and password for this conference call. This structure—announcing a call to discuss results—is the defining characteristic of an Earnings Call or similar results discussion event. Since the definition for Call Transcript (CT) is 'Full text transcript of company conference calls (like earnings calls with Q&A)', and this document is the announcement *of* that call, it is most accurately classified as the announcement/material related to the call itself. However, given the options, the announcement of a call to discuss results (often earnings or clinical trial updates) strongly aligns with the context of a Call Transcript (CT) event, even if this specific document is the invitation rather than the transcript itself. If the document were the transcript, it would be CT. Since it is the announcement of the call where results will be discussed, and there is no specific category for 'Conference Call Announcement', the closest fit related to the event type is CT, or potentially ER if the results were financial earnings, but here they are clinical results. Given the focus on the call details, CT is the most appropriate classification for materials surrounding a results call.
2016-09-22 French
Quantum Genomics Announces Conference Call to Review Top-line Results from Phase IIa Study of QGC001 in Hypertension
Call Transcript Classification · 95% confidence The document is explicitly titled as a "Press release" and announces a "Conference Call to Review Top-line Results from Phase IIa Study of QGC001 in Hypertension." It provides specific details for accessing this conference call (date, time, dial-in numbers, passcode). This content perfectly matches the definition of a Call Transcript (CT) if it were the transcript itself, or more accurately, an announcement leading up to a call where results will be discussed. Since the document is short (2722 chars) and its primary function is to announce the event and provide access details, it is most closely related to the event itself. However, none of the codes explicitly cover the *announcement* of an earnings/results call, only the release of results (ER) or the transcript (CT). Given the context of discussing 'top-line results' and hosting a call, this is highly indicative of an earnings-related event. Since it is not the actual results release (ER) or the transcript (CT), and it is an announcement about a discussion of results, the closest fit among the options that deal with results discussion events is the Call Transcript (CT), as these announcements precede the CT. Alternatively, if the focus is purely on the announcement mechanism, it could be RNS. However, because the core subject is the discussion of clinical/financial results via a conference call, CT is the most relevant category for the event being scheduled. Given the options, and recognizing this is the setup for a discussion of results, I will classify it as CT, acknowledging it is the announcement *for* the call, not the transcript itself, but it is the most relevant event type listed.
2016-09-22 English
Quantum Genomics communiquera le 29 septembre 2016 sur les résultats de l'étude de phase IIa dans l'hypertension artérielle
Report Publication Announcement Classification · 98% confidence The document is a press release dated September 12, 2016, announcing that Quantum Genomics will communicate the results of its Phase IIa clinical study for arterial hypertension on September 29, 2016. This document is not the actual report (like IR or ER), nor is it a transcript or a formal regulatory filing like a 10-K. It is an announcement about the future publication or communication of results. According to Rule 2, if a document announces the timing of a report release, it should be classified as a Report Publication Announcement (RPA).
2016-09-12 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.